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Abstract: The phenotypical consequences of a combined deficiency of the Fas-Fas Ligand 
(FasL) and one or both Tumor Necrosis Factor (TNF) signaling pathways were investigated. 
Mice, which expressed a non-functional FasL suffered from a pathological accumulation of 
both B and T cells leading to splenomegaly and lymphadenopathy and, depending on the 
genetic background, pathogenic self-reactive antibodies (generalized lymphoproliferative 
disorder (gld)-phenotype). If mice additionally lacked TNF, they displayed a significantly 
ameliorated gld-phenotype while TNF Receptor-1-deficient gld mice (B6.gld.TNFR1−/−) 
displayed a more severe phenotype. To complement this combination, we also generated 
TNF Receptor-2-deficient gld mice (B6.gld.TNFR2−/−). Both double knockouts followed in 
their splenic structure the respective TNFR contribution to the phenotype. TNFR1−/− mice 
showed an absence of B cell follicles in the spleen while TNFR2−/− mice were comparable 
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to WT mice. In general, we demonstrated a strong contribution of both TNFR signaling 
pathways to the symptoms of gld with the notable exception of splenomegaly where only 
TNFR1−/− played a role. 
Keywords: autoimmunity; tumor necrosis factor; tumor necrosis factor receptor;  
gene-deficient models 
 
1. Introduction 
Apoptosis is fundamental for the maintenance of both central and peripheral tolerance and the 
contraction of effector responses in the periphery [1]. Consequently, inhibition of apoptosis leads to 
lymphoaccumulation and a predisposition to autoimmune disease [2]. Apoptosis facilitates cellular 
homeostasis in the immune system via the extrinsic pathway [1,3], which is triggered by cytokines of 
the TNF family of ligands [4,5]. More specifically, the pro-apoptotic cytokine FasL is expressed on a 
variety of immune cells such as CD8+ T cells and is involved in the induction of apoptosis via its cognate 
receptor Fas (FasR) [1]. Two different spontaneous recessive murine mutations have been described that 
caused the adjournment of immune homeostasis and resulted in massive lymphoaccumulation 
accompanied by symptoms of an autoimmune disorder comparable to Systemic Lupus Erythematosus 
(SLE) [6,7]. Consequently, these mutation-carrying strains have been named lymphoproliferation (lpr) 
and generalized lymphoproliferative disorder (gld) [7]. As underlying cause of the disorders a complete 
loss of Fas as well as a loss-of-function mutation of FasL have been identified [5]. Another member of 
the TNF family, the name giving cytokine TNF, can also trigger apoptosis via the TNFR1 [8]. The 
involvement of TNFR-1 in the lpr phenotype has been analyzed and an additive pathological activity of 
Fas and TNFR1 has been demonstrated [9] while a combination of gld and TNF resulted in an attenuated 
form of lymphadenopathy [10]. To further dissect the signaling pathways involved in the autoimmune 
pathogenesis of the gld mouse strain gld.TNFR1−/− and gld.TNFR2−/− knockout mouse strains were 
generated and their phenotype was analyzed to compare the phenotypic outcomes from the loss of  
these receptors. 
2. Results and Discussion 
2.1. Comparison of the Overall Phenotype of B6.gld.TNFR1−/− and B6.gld.TNFR2−/− Mice 
We analyzed the phenotypical consequences of the deletions of tnfr1 and tnfr2 in combination with 
the loss-of-function of fasL and tested the B6.gld.TNFR1−/− and B6.gld.TNFR2−/− mouse strains [9,10] 
for the influence of these combined mutations on hallmarks of the gld phenotype: The long term survival 
of the mice and the extent of the splenomegaly. Furthermore, we determined the splenic CCL21 
expression because specifically the absence of TNF prevents the expression of this chemokine in 
B6.gld.TNF−/− mice [11]. 
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Interestingly, the length of survival of the two genotypes was very similar (Figure 1A) and a 
comparison to previously published data showed that it was not significantly different from the B6.gld 
strain but shorter than B6.gld.TNF−/− mice ((B6.gld.TNFR1 and 2−/− strain: 40 weeks 50% survival; 
B6.gld.TNF−/− mice: 70 weeks 50% survival; [12]). We could not detect a significant difference between 
the survival times of male and female B6.gld.TNFR1−/− mice (males: n = 20; females: n = 8) using a log 
rank (Mantel-Cox) test or Gehan-Breslow Wilcoxon test. 
 
 
(A) (B) 
 
(C) 
Figure 1. Comparative analysis of B6.gld.TNFR1−/− and B6.gld.TNFR2−/− mice with regard 
to morbidity, spleen weight, intracellular cytokine FACS and chemokine ELISA: (A) A 
similar progression of the clinical gld syndrome is observed in both B6.gld.TNFR1−/− and 
B6.gld.TNFR2−/− mice. An analysis of a survival curve with both a log rank (Mantel-Cox) 
test or Gehan-Breslow Wilcoxon test did not demonstrate a significant difference between 
the two genotypes (B6.gld.TNFR1−/− mice: n = 47; B6.gld.TNFR2−/− mice: n = 19); (B) The 
B6.gld.TNFR1−/− mice develop a significantly larger spleen. A comparison of WT (n = 3), 
gld (n = 6), B6.gld.TNFR1−/− (n = 22) and B6.gld.TNFR2−/− mice (n = 15) showed a 
significant larger spleen in the B6.gld.TNFR1−/− strain as compared to B6.WT or 
B6.gld.TNFR2−/− spleens (one way Anova, p ≤ 0.001). All spleens in this comparison were 
harvested for this publication. *: p ≤ 0.05; ns: not significant; (C) The expression of CCL21 
in the spleen is intermediate in both B6.gld.TNFR1−/− and B6.gld.TNFR2−/− mice (white 
bars). The titre of CCL21 in spleen tissue was determined by ELISA and was found to be 
9.5 (n = 19) and 7 ng/mL (n = 15), respectively. The data for B6.WT, B6.gld and B6.TNFR1 
(striped bars) were published previously and were added to this figure as comparison [12],  
***: p ≤ 0.01. 
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In contrast, the size of the spleens was markedly different between the B6.gld.TNFR1−/− and 
B6.gld.TNFR2−/− mouse strains. While the spleens of the B6.gld.TNFR1−/− mice almost reached the size 
of B6.gld spleens [9] the B6.gld.TNFR2−/− spleens remained relatively small and were found to be only 
marginally bigger than B6.WT spleens (Figure 1B). The substantial size difference of spleens from 
B6.gld.TNFR1−/− (Figure 1B) and B6.gld mice [12] which were bred in our animal facility to previously 
published data of MRL.lpr.TNFR1−/− mice [9] can be explained with the increased susceptibility of the 
MRL strain to the development of the autoimmune phenotype in general, and of splenomegaly and 
lymphadenopathy, in particular [7]. A phenotypic comparison of the TNFR1−/− and TNFR2−/− mice was 
not carried out. A gross analysis of the cellularity of the spleen of both genotypes has been published 
previously [13] and could not find a difference to the WT strain [14]. 
Previously it has been shown that B6.gld mice overexpress CCL21 and that the absence of TNF 
specifically prevents this overexpression reducing autoimmune pathology [11]. It was hypothesized that 
this TNF-dependent CCL21 expression was one of the underlying causes of the accumulation of  
T cells and B cells in the peripheral lymphoid organs. Since the B6.gld.TNFR1−/− and B6.gld.TNFR2−/− 
mouse strains displayed a significant difference in the size of their spleen we tested the expression of 
CCL21 in these mouse strains using a CCL21-specific capture ELISA as compared to B6.WT, B6.gld 
and B6.TNFR1−/− genotypes which had been published previously [11,12]. It showed that the expression 
level of CCL21 in B6.gld.TNFR1−/− and B6.gld.TNFR2−/− mouse spleens was not significantly different 
from each other or from B6.WT spleens but substantially lower as in B6.gld mice (Figure 1C). 
The cytokine TNF and its pro-inflammatory receptor TNFR1 are central for a protective innate 
immune response in particular to intracellular pathogens such as parasites [15] or bacteria [16] while the 
functions of the second TNF signaling pathway are still not entirely resolved and are probably involved 
in immune homeostasis [17]. However, the pro-inflammatory signaling pathway is also associated with 
chronic inflammation, which is observed in autoimmune diseases such as inflammatory bowel disease 
(IBD) or rheumatoid arthritis or in a mouse model of systemic lupus erythematosus, gld [16]. The 
combination of different gene-deficient strains allowed us to investigate how either of the two TNFR-
pathways or a combination of both contributed to the severe autoimmune disorder gld caused by the absence 
of a functional FasR-FasL signaling transduction. First, a TNFR1 deficiency on a gld.MRL background 
leads to a stronger and more accelerated phenotype with a more pronounced splenomegaly and increased 
titres of autoantibodies [9]. Our results confirm this outcome to some extent but put some emphasis back 
on the role of the MLR background, which has been described as autoimmune-prone [18,19]. In this 
comparative study of B6.gld.TNFR1−/− mice we observe a longer mean survival time than B6.gld  
mice and significant splenomegaly and lymph node hypertrophy contrasted with a normal CCL21 
expression [10,11]. This could be explained because the absence of TNFR1 can be responsible for the 
increased activation of TNFR2 signaling pathways [20] and it could lead to an increased proliferation of 
T cells [21]. Concurrently, the higher level of NF-kB activation could also antagonize the TNF-induced 
TNFR2-mediated apoptosis and thus cause lymphoaccumulation [22]. Second, a previously published 
investigation of the gld/TNF−/− phenotype on a B6 background showed a strong attenuation of the gld 
symptoms and an absence of splenomegaly [10]. This phenotype could have been caused by the absent 
proliferative signal through the TNF-TNFR2 signaling pathway and the loss of the anti-apoptotic 
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influence of TNF on T cells [10]. Consequently, we had hypothesized that TNFR2 contributed 
significantly to the observed autoimmune symptoms and we concluded that a combination of a  
TNFR2-deficient mouse strain with gld would abrogate most of the phenotype and would be more 
benign in its phenotype. This was only the case with regard to splenomegaly but not the survival time of 
B6.gld.TNFR2−/− mice. 
2.2. Transfer of CD4−/CD8− DN T Cells into TNFR Double Knockouts Follows the Respective TNFR 
Phenotype and Results in Migration to the Bridging Channels or Ends in the B Cell Area 
The separation and shape of T and B cell areas in the spleen are changed by TNF [23] or TNFR1 
gene-deficiencies [24] and well-defined B cell follicles are replaced by rim-like B cell structures. (Figure 
2C; [23,25]). In B6.gld and B6.gld.TNF−/− mice an additional population of T cells is detectable that is 
double negative (DN) for CD4 and CD8 [26]. Previous experiments have shown that the DN T cell 
populations of B6.gld and B6.gld.TNF−/− mice were positive for CXCR5 and migrated in vitro in response 
to CXCL13 but did not express CCR7 [11,27]. After adoptive transfer into a wildtype mouse this population 
stopped at the splenic bridging channel and proceeded only very slowly into the follicle despite the 
expression of CXCR5 [27]. This DN T cell population was isolated using flow cytometry, labeled with 
CFSE and used to test the contribution of structures such as follicles and bridging channels to the cell 
migration in B6.gld.TNFR1−/− and B6.gld.TNFR2−/− mouse spleens. The control transfer of DN T cells 
into B6.WT confirmed the stop at the bridging channels (Figure 2A). In TNF- and TNFR-deficient mice 
the migration patterns of DN T cells followed the structure of the follicles. The spleens of 
B6.gld.TNFR1−/− and B6.gld.TNF−/− mice displayed rim-like B cell structures without follicular 
compartmentalization and the DN T cells entered the B cell area without further delay and were 
distributed evenly throughout the B cell area (Figure 2C,D). In contrast, B6.gld and B6.gld.TNFR2−/− 
spleens showed a follicular structure comparable to B6.WT spleens. In these genotypes the transferred DN 
T cells relocated accordingly and paused at the bridging channels (Figure 2B,E). 
In a previous study we had correlated the expression of CCL21 with the gld-phenotype and had been 
able to demonstrate that the additional absence of TNF, which caused the disruption of both TNFR 
signaling pathways and a significant reduction of the CCL21 expression, resulted in a more benign 
pathology [11]. The implied causal connection between chemokine expression and autoimmune 
pathology has to be reconsidered. In our current study we show a comparable expression of the 
chemokine CCL21 in both B6.gld.TNFR1−/− and B6.gld.TNFR2−/− spleen yet significantly different 
cellularity of the lymphoid organs, which is contrasted by migration of DN T cells that purely followed 
the structure of the splenic architecture. To finally address this question about an influence of CCL21 
on the gld-pathology we will need to overexpress the chemokine in the absence of TNF. 
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Figure 2. The spleen phenotype is determined by TNF-TNFR signaling. B6.WT (A), B6.gld 
(B), B6.gld.TNF−/− (C), B6.gld.TNFR1−/− (D) and B6.gld.TNFR2−/− (E) spleens were 
analyzed histologically after transfer of CFSE-labeled DN T cells. Using mAbs for IgM (red) 
and IgD (blue) the outline of the T cell area (T), B cell follicles (F) and the marginal zone 
(MZ) were determined. The bridging channels (arrows) are clearly visible in B6.WT, B6.gld, 
and B6.gld.TNFR2−/− spleens (10× objective magnification). The scale bar equates to 250 µm. 
3. Experimental Section 
3.1. Mouse Strains 
The C57Bl/6(B6).gld.TNFR1−/− and B6.gld.TNFR2−/− mouse strains were established by 
backcrossing B6.gld [7] with B6.TNFR1−/− or B6.TNFR2−/− deficient mice, respectively [13] followed 
by inter-crossing of F1 progeny to achieve homozygosis. Mice homozygous for both the gld mutation 
and TNFR1 or TNFR2 deficiency were selected using screening primers outlined in previous 
publications [13,28]. Additional mouse strains used were B6.FasL.TNF−/− [10] and B6.TNF−/− [23]. The 
genetically unmodified mouse strain C57BL/6 was used as control. All animals were kept under specific 
pathogen free conditions in IVC units at the animal research facilities of the Comparative Genomics 
Centre, James Cook University, Townsville, Australia and the Menzies Research Institute Tasmania, 
Hobart, Australia. Mice used for the phenotypic comparison (Figure 1) were kept Comparative 
Genomics Centre, James Cook University, Townsville. Mice of both sexes were used. 
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3.2. Ethics Statement 
Care of animals was in accord with institution guidelines of James Cook University, Townsville and 
the University of Tasmania, Hobart. 
3.3. CCL21 Elisa 
The amount of CCL21 in spleen tissue was determined as described [11] using a Capture-ELISA with 
purified and biotinylated CCL21 specific antibodies for capture and detection, respectively (R&D 
Systems, Minneapolis, MN, USA), and recombinant murine CCL21 (R&D Systems) as standard. The 
resulting chemokine concentration was normalized by tissue weight. 
3.4. Fluorescence Immunohistology 
Spleens were harvested, frozen in Optimal Cutting Temperature (OCT) medium and cut in sections 
(8 µm). Fluorescence immunohistology was performed as described in detail elsewhere [29]. Antibodies 
used were: Rat anti mouse µ heavy chain (Cy5), rat anti mouse  heavy chain, rat anti-mouse B220 
(purified or biotinylated; clone RA3-6B2; BD Biosciences). Biotinylated B220 was revealed using 
Streptavidin Alexa 594 or 546, respectively. Purified B220 was revealed with goat anti rat Alexa 488 
(Invitrogen, Sydney, Australia). The sections were analyzed using an Olympus BX51 microscope 
(Olympus, Sydney, Australia) with a high-sensitivity gray-scale digital camera (Olympus Optotronics, 
Olympus) and Magnifier software (Olympus). 
3.5. Flow Cytometry 
The cells were stained for CD4 (RM4-5, PerCP-Cy5.5) and CD3 (145-2C11, APC-Cy7). Intracellular 
cytokine flow cytometry was performed as described in detail elsewhere [10] using Cytofix-Cytoperm 
(BD Biosciences, North Ryde, NSW, Australia) following the manufacturer’s instructions and rat anti 
mouse IFN- (XMG1.2, Alexa Fluor-488). Data were collected using a FACS-Calibur flow cytometer 
and analyzed with Cell-Quest software (BD Biosciences). 
3.6. Adoptive Cell Transfer 
Lymphocytes were harvested from spleens and lymph nodes of B6.gld mice and CD4− CD8− TCR+ 
T cells were isolated using a BD Aria cell sorter (BD Biosciences). The T cells were labelled with 
carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes, Invitrogen) as described [30] and 
transferred intravenously into B6.WT, B6.gld, B6.gld.TNF−/−, B6.gld.TNFR1−/− and B6.gld.TNFR2−/− mice. 
The spleens of the recipients were harvested 16–24 h after transfer and analysed using 
immunofluorescence after a co-staining with anti µ and  heavy chain antibodies. 
4. Conclusions 
Our investigation of B6.gld.TNFR1−/− and B6.gld.TNFR2−/− mice has demonstrated that the clinical 
outcome in both genotypes followed the respective phenotype, which had been caused by either a 
Antibodies 2015, 4 8 
 
deficient TNF-TNFR1 or TNF-TNFR2 signaling pathway. Both genotypes expressed CCL21 at WT 
level, but while B6.gld.TNFR1−/− mice showed a modified spleen structure comparable to the  
TNF-knockout the B6.gld.TNFR2−/− strain resembled a WT spleen. The data presented formally prove 
that the presence of the TNF-TNFR2 axis alone contributes to an augmentation of the disorder while the 
sole presence of TNF-TNFR1 abolishes some effects of the consequences of an inactive FasL such as 
splenomegaly. Interestingly, a complete absence of TNF signaling does attenuate the gld phenotype 
which points again at an actively detrimental role of an existing TNF-TNFR2 signaling pathway but 
could also be due to the anti-apoptotic effect TNF has specifically on T cells. Taken together, we 
demonstrate that an intact TNFR1 pathway (maintained in the B6.gld.TNFR2−/− strain) plays a 
significant role in the prevention of splenomegaly, which is typical for the gld phenotype. For the first 
time we are able to formally proof that in the absence of the TNF-TNFR2 signaling pathway 
splenomegaly is prevented yet survival is still reduced. 
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